Publicaciones en las que colabora con Carlos Panizo Santos (21)

2024

  1. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

2023

  1. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

  2. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

2019

  1. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

  2. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

    Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates

    Journal of Immunological Methods, Vol. 442, pp. 54-58

  2. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study

    European Journal of Haematology, Vol. 98, Núm. 1, pp. 38-43

2013

  1. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

    Blood, Vol. 122, Núm. 8, pp. 1448-1454

2011

  1. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma

    Journal of Neuro-Oncology, Vol. 103, Núm. 3, pp. 603-609

2010

  1. Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease

    Haematologica

2009

  1. Splenic marginal zone lymphoma with Evans' syndrome, autoimmunity, and peripheral gamma/delta T cells

    Annals of Hematology

2008

  1. Systemic lupus erythematosus and Franklin's disease: When the somatic mutation mechanism makes a mistake

    Rheumatology

2003

  1. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized, double-blind clinical trial

    Journal of Thrombosis and Haemostasis, Vol. 1, Núm. 3, pp. 425-432

  2. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: Clinical and genetic features of two cases

    Cancer Genetics and Cytogenetics, Vol. 143, Núm. 2, pp. 178-181

2002

  1. Acquired inhibitor of the intrinsic pathway in a non-haemophilic patient. Control of bleeding by recombinant factor VIIa [11]

    British Journal of Haematology

2001

  1. Caso clínico: Mujer de 21 años con episodios trombóticos de repetición

    Medicine: Programa de Formación Médica Continuada Acreditado, Vol. 8, Núm. 53, pp. 2863-2865

  2. Inhibidores directos de la trombina: Su papel en el tratamiento de la trombosis arterial y venosa

    Medicina Clinica, Vol. 116, Núm. 2, pp. 63-74